Our present preclinical intervention study for the first time provides evidence that cardamom EO treatment of C. jejuni-infected microbiota-depleted IL-10−/− mice resulted in lower intestinal pathogen burdens, improved clinical outcome, less distinct macroscopic and microscopic inflammatory sequelae, and in diminished pro-inflammatory mediator secretion not only in the intestinal tract, but also in extra-intestinal and, remarkably, even in systemic compartments during acute campylobacteriosis. This evidence concerns the gene IL10 and campylobacteriosis.